MassIVE MSV000091389

Partial Public PXD040535

The HLA class-I immunopeptidomes of AAV capsid proteins

Subscribe Comment Reanalyze Spectra Add Reanalysis

Description

Introduction: Cellular immunity is one of the main factors affecting sustained expression of gene therapies. AAV capsid-specific CD8+ T cells recognize peptides that are loaded on HLA class I molecules by cells that have been infected or transduced with AAVs. Previous studies performed by others have identified several peptides that activate CD8+ T cells, however the entire repertoire of naturally displayed peptides is unknown. Methods: Using MHC-associated peptide proteomics, we describe the HLA class I immunopeptidomes of AAV2, AAV6 and AAV9 capsids. Monocyte-derived dendritic cells (MDDCs) were isolated from a panel of 13 healthy donors that have diverse alleles representing more than 50% of the US population. MDDCs were transfected with mRNA encoding for the different AAV capsids. 6 hours post transfection, cells were lysed and peptide:HLA complexes were immunoprecipitated. Peptides were eluted and analyzed by mass spectrometry and PEAKS bioinformatic algorithms. Results: The HLA-I peptides are distributed along the entire capsids but the number of AAV9-derived peptides was significantly higher than for AAV2 or AAV6. We identified a few peptides that had been described before and are immunogenic. We also observed 14 peptides that are highly conserved among the serotypes. Finally, we observed that more than 60% of the HLA-I peptides are contained within HLA-II clusters. Discussion: This work is the first comprehensive study identifying the naturally displayed HLA class I peptides derived from the capsid of AAVs and expands on previous studies that have identified immunogenic peptides. The results from this study can be used to generate peptide pools to assess immunogenicity risk of gene therapies in the clinic. [doi:10.25345/C52F7K18M] [dataset license: CC0 1.0 Universal (CC0 1.0)]

Keywords: AAV ; HLA class I ; CD8+ ; Immunogenicity

Contact

Principal Investigators:
(in alphabetical order) 		Carlos Brito, Eli Lilly & Company, United States
Submitting User: cabritos
Number of Files:
Total Size:
Spectra:
Subscribers:
 
Owner Reanalyses
Experimental Design
    Conditions:
    Biological Replicates:
    Technical Replicates:
 
Identification Results
    Proteins (Human, Remapped):
    Proteins (Reported):
    Peptides:
    Variant Peptides:
    PSMs:
 
Quantification Results
    Differential Proteins:
    Quantified Proteins:
 
Browse Dataset Files
 
FTP Download Link (click to copy):

Species

Instrument

Modifications

- Dataset Reanalyses

+ Dataset History

Click here to queue conversion of this dataset's submitted spectrum files to open formats (e.g. mzML). This process may take some time.

When complete, the converted files will be available in the "ccms_peak" subdirectory of the dataset's FTP space (accessible via the "FTP Download" link to the right).
Number of distinct conditions across all analyses (original submission and reanalyses) associated with this dataset.

Distinct condition labels are counted across all files submitted in the "Metadata" category having a "Condition" column in this dataset.

"N/A" means no results of this type were submitted.
Number of distinct biological replicates across all analyses (original submission and reanalyses) associated with this dataset.

Distinct replicate labels are counted across all files submitted in the "Metadata" category having a "BioReplicate" or "Replicate" column in this dataset.

"N/A" means no results of this type were submitted.
Number of distinct technical replicates across all analyses (original submission and reanalyses) associated with this dataset.

The technical replicate count is defined as the maximum number of times any one distinct combination of condition and biological replicate was analyzed across all files submitted in the "Metadata" category. In the case of fractionated experiments, only the first fraction is considered.

"N/A" means no results of this type were submitted.
Originally identified proteins that were automatically remapped by MassIVE to proteins in the SwissProt human reference database.

"N/A" means no results of this type were submitted.
Number of distinct protein accessions reported across all analyses (original submission and reanalyses) associated with this dataset.

"N/A" means no results of this type were submitted.
Number of distinct unmodified peptide sequences reported across all analyses (original submission and reanalyses) associated with this dataset.

"N/A" means no results of this type were submitted.
Number of distinct peptide sequences (including modified variants or peptidoforms) reported across all analyses (original submission and reanalyses) associated with this dataset.

"N/A" means no results of this type were submitted.
Total number of peptide-spectrum matches (i.e. spectrum identifications) reported across all analyses (original submission and reanalyses) associated with this dataset.

"N/A" means no results of this type were submitted.
Number of distinct proteins quantified across all analyses (original submission and reanalyses) associated with this dataset.

Distinct protein accessions are counted across all files submitted in the "Statistical Analysis of Quantified Analytes" category having a "Protein" column in this dataset.

"N/A" means no results of this type were submitted.
Number of distinct proteins found to be differentially abundant in at least one comparison across all analyses (original submission and reanalyses) associated with this dataset.

A protein is differentially abundant if its change in abundance across conditions is found to be statistically significant with an adjusted p-value <= 0.05 and lists no issues associated with statistical tests for differential abundance.

Distinct protein accessions are counted across all files submitted in the "Statistical Analysis of Quantified Analytes" category having a "Protein" column in this dataset.

"N/A" means no results of this type were submitted.
This dataset may not contain all raw spectra data as originally deposited in PRIDE. It has been imported to MassIVE for reanalysis purposes, so its spectra data here may consist solely of processed peak lists suitable for reanalysis with most software.